Umlobi: Gregory Harris
Usuku Lokudalwa: 14 Epreli 2021
Ukuvuselela Usuku: 21 Unovemba 2024
Anonim
Mode of action of Saccharomyces boulardii CNCM I-745
Ividiyo: Mode of action of Saccharomyces boulardii CNCM I-745

-Delile

ISaccharomyces boulardii imvubelo. Phambilini bekukhonjwa njengohlobo oluyingqayizivele lwemvubelo. Manje kunenkolelo yokuthi inguhlobo lweSaccharomyces cerevisiae. Kepha iSaccharomyces boulardii yehlukile kwezinye izinhlobo zeSaccharomyces cerevisiae eyaziwa kakhulu ngokuthi imvubelo yomenzi wentselo kanye nemvubelo yombhaki. ISaccharomyces boulardii isetshenziswa njengomuthi.

ISaccharomyces boulardii isetshenziswa kakhulu ekwelapheni nasekuvimbeleni isifo sohudo, kufaka phakathi izinhlobo ezithathelwanayo ezifana nohudo lwe-rotaviral ezinganeni. Inobunye ubufakazi bokusetshenziswa kwezinye izinhlobo zohudo, izinduna, kanye nokutheleleka kokugaya ukudla okungaholela ezilondeni.

Isifo seCoronavirus 2019 (COVID-19): Abukho ubufakazi obuhle bokusekela ukusebenzisa iSaccharomyces boulardii ye-COVID-19. Landela izindlela zokuphila ezinempilo nezindlela zokuvikela ezifakazelwe esikhundleni salokho.

Imibhalo Yemvelo Yemininingwane Ephelele ukukala ukusebenza ngokuncike ebufakazini besayensi ngokwesilinganiso esilandelayo: Okusebenzayo, Okungenzeka Kusebenze, Okungenzeka Kusebenze, Okungenzeka Kungasebenzi, Cishe Okungaphumeleli, Ukungasebenzi, Nobufakazi Obunganele Bokulinganisa.

Izilinganiso zokusebenza ze IMINIKELO YABANGCWELE BOULARDII zimi kanje:


Cishe iyasebenza ...

  • Uhudo. Ucwaningo lukhombisa ukuthi ukunikeza iSaccharomyces boulardii ezinganeni ezinesifo sohudo kunganciphisa ukuthi kuhlala isikhathi esingakanani kuze kufike osukwini olungu-1. Kepha iSaccharomyces boulardii ibonakala ingasebenzi kangako kunemithi ejwayelekile yohudo, efana ne-loperamide (Imodium).
  • Uhudo olubangelwa yi-rotavirus. Ukunikeza izinsana nezingane ezinesifo sohudo esibangelwa i-rotavirus kunganciphisa ukuthi uhudo luhlala isikhathi esingakanani ngosuku.

Kungenzeka kusebenze ...

  • Izinduna. Ucwaningo lukhombisa ukuthi ukuthatha iSaccharomyces boulardii ngomlomo kusiza ukuthuthukisa ukubukeka kwezinduna.
  • Uhudo kubantu abathatha ama-antibiotic (isifo sohudo esihlobene ne-antibiotic). Ucwaningo oluningi lukhombisa ukuthi iSaccharomyces boulardii ingasiza ukuvimbela isifo sohudo kubantu abadala nasezinganeni ezilashwa ngama-antibiotic. Kuzo zonke iziguli eziyi-9-13 eziphathwa nge-Saccharomyces boulardii ngenkathi zelashwa ngama-antibiotic, umuntu oyedwa omncane uzoba nohudo oluhlobene nama-antibiotic.
  • Ukutheleleka komgudu wamathumbu ngamagciwane abizwa ngeClostridium difficile. Ukuthatha iSaccharomyces boulardii kanye nemithi elwa namagciwane kubonakala kusiza ukuvimbela isifo sohudo esihambisana neClostridium difficile ukuthi singaphinde sivele kubantu abanomlando wokuphindeka. Ukuthatha iSaccharomyces boulardii kanye nama-antibiotic nakho kubonakala kusiza ukuvimbela iziqephu zokuqala zohudo oluhambisana neClostridium difficile. Kepha ochwepheshe abancomi ukuthi kusetshenziswe iSaccharomyces yokuvikela iziqephu zokuqala.
  • Ukutheleleka kokugaya ukudla okungaholela ezilondeni (Helicobacter pylori noma H. ​​pylori). Ukuthatha iSaccharomyces boulardii ngomlomo kanye nokwelashwa okujwayelekile H. pylori kusiza ekwelapheni lesi sifo. Cishe abantu abayi-12 badinga ukwelashwa nge-Saccharomyces boulardii eyengeziwe ngesiguli esisodwa ebesizohlala sinegciwane ukuze silapheke. Ukuthatha i-Saccharomyces boulardii kusiza nokuvikela imiphumela emibi efana nohudo kanye nesicanucanu okwenzeka ngokwelashwa okujwayelekile kwe-H. pylori. Lokhu kungasiza abantu ukuthi baqede imishanguzo yabo ejwayelekile kaH. Pylori.
  • Uhudo kubantu abane-HIV / AIDS. Ukuthatha iSaccharomyces boulardii ngomlomo kubonakala kunciphisa isifo sohudo esihlobene ne-HIV.
  • Isifo esibi samathumbu ezinganeni ezingakazalwa ngaphambi kwesikhathi (necrotizing enterocolitis noma i-NEC). Ucwaningo oluningi lukhombisa ukuthi ukunikeza iSaccharomyces boulardii ukusungula izingane ngaphambi kokuzalwa kuvimbela i-NEC.
  • Uhudo lwabahambi. Ukuthatha iSaccharomyces boulardii ngomlomo kubonakala kuvimbela uhudo lwabahambi.

Kungenzeka kungasebenzi ku ...

  • Ukutheleleka ngegazi (sepsis). Ucwaningo lukhombisa ukuthi ukunikela ngeSaccharomyces boulardii ezinsaneni ezizalwa ngaphambi kwesikhathi akuvimbeli i-sepsis.

Ubufakazi obanele bokukala ukusebenza kwe ...

  • Ukutheleleka kwamathumbu okubangela isifo sohudo (ikholera). ISaccharomyces boulardii kubonakala ngathi ayizithuthukisi izimpawu zekholera, noma ngabe inikezwa ngemithi ejwayelekile.
  • Amakhono wokukhumbula nokucabanga (umsebenzi wokuqonda). Ucwaningo lwakuqala lukhombisa ukuthi ukuthatha iSaccharomyces boulardii akusizi abafundi ukuthi benze kangcono ezivivinyweni noma kwehlise ingcindezi yabo.
  • Uhlobo lwesifo samathumbu esivuthayo (isifo seCrohn). Ukuthatha iSaccharomyces boulardii kubonakala kunciphisa inani lokuhamba kwamathumbu kubantu abanesifo seCrohn. Ucwaningo lwakuqala lukhombisa nokuthi ukuthatha iSaccharomyces boulardii kanye ne-mesalamine kungasiza abantu abanesifo seCrohn ukuthi bahlale isikhathi eside. Kepha ukuthatha iSaccharomyces boulardii kukodwa akubonakali kusiza abantu abanesifo seCrohn ukuthi bahlale ekuxolelweni isikhathi eside.
  • ICystic fibrosis. Ucwaningo lwakuqala lukhombisa ukuthi ukuthatha iSaccharomyces boulardii ngomlomo akwehlisi ukutheleleka kwemvubelo emkhakheni wokugaya ukudla kwabantu abane-cystic fibrosis.
  • Ukwehluleka kwenhliziyo. Ucwaningo lwasekuqaleni lukhombisa ukuthi ukuthatha iSaccharomyces boulardii kungahle kuthuthukise ukusebenza kwenhliziyo kubantu abanenhliziyo ehlulekayo.
  • I-cholesterol ephezulu. Ucwaningo lokuqala lukhombisa ukuthi iSaccharomyces boulardii kubonakala ngathi ayithinti amazinga e-cholesterol.
  • Ukuphazamiseka kwesikhathi eside kwamathumbu amakhulu okubangela ubuhlungu besisu (i-irritable bowel syndrome noma i-IBS). Ucwaningo lukhombisa ukuthi ukuthatha iSaccharomyces boulardii kuthuthukisa izinga lempilo kubantu abane-IBS. Kepha iSaccharomyces boulardii kubonakala ngathi ayizithuthukisi izimpawu eziningi ze-IBS ezinjengobuhlungu besisu, ukuphuthuma, noma ukuqunjelwa.
  • Ukutheleleka kwamathumbu ngama-parasites. Ucwaningo lwakuqala lukhombisa ukuthi ukuthatha iSaccharomyces boulardii ngomlomo kanye nama-antibiotics kunciphisa isifo sohudo nobuhlungu besisu kubantu abanezifo ze-amoeba.
  • Ukuphuzi kwesikhumba ezinganeni (i-jaundice ye-neonatal). Ezinye izinsana ziba ne-jaundice ngemuva kokuzalwa ngenxa yamazinga aphezulu e-bilirubin. Ukunikeza iSaccharomyces boulardii ukuqeda izinsana kungavimbela i-jaundice futhi kunciphise isidingo se-phototherapy kwinani elincane lalezi zingane. Kodwa akwaziwa ukuthi iSaccharomyces boulardii inciphisa ubungozi be-jaundice ezinganeni ezisengozini. Ukunikeza izingane i-Saccharomyces boulardii kanye ne-phototherapy akwehlisi amazinga e-bilirubin kangcono kune-phototherapy kuphela.
  • Izinsana ezizalwe zinesisindo esingaphansi kwama-2500 amagremu (amakhilogremu ama-5, ama-ounces ayi-8). Ukunikeza isengezo seSaccharomyces boulardii ngemuva kokuzalwa kubonakala kuthuthukisa ukuzuza kwesisindo nokondla ezinganeni ezizalwe ngaphambi kwesikhathi ezinesisindo esiphansi sokuzalwa.
  • Ukukhula ngokweqile kwamagciwane emathunjini amancane. Ucwaningo lwakuqala lukhombisa ukuthi ukwengeza iSaccharomyces boulardii ekwelashweni ngama-antibiotics kunciphisa ukukhula kwamagciwane emathunjini kangcono kunama-antibiotic kuphela.
  • Uhlobo lwesifo samathumbu esivuthayo (ulcerative colitis). Ucwaningo lwakuqala lukhombisa ukuthi ukufaka iSaccharomyces boulardii ekwelashweni okujwayelekile kwe-mesalamine kunganciphisa izimpawu kubantu abane-ulcerative colitis emnene ukuya kokuphakathi.
  • Izilonda zekhankatha.
  • Umkhuhlane imfiva.
  • Isifuba.
  • Ukungabekezelelani kwe-Lactose.
  • Isifo seLyme.
  • Ubuhlungu bemisipha obubangelwa ukuzivocavoca umzimba.
  • Ukutheleleka kwe-Urinary tract (UTIs).
  • Ukutheleleka ngemvubelo.
  • Ezinye izimo.
Kudingeka ubufakazi obengeziwe ukukala iSaccharomyces boulardii ngalokhu kusetshenziswa.

ISaccharomyces boulardii ibizwa nge- "probiotic," umzimba onobungane osiza ukulwa nezinto ezibanga izifo esiswini njengamagciwane nemvubelo.

Lapho ithathwa ngomlomo: Saccharomyces boulardii kuyinto CISHE UVIKILE kubantu abaningi abadala lapho bethathwe ngomlomo izinyanga ezifika kwezili-15. Kungadala igesi kwabanye abantu. Imvamisa, kungadala ukutheleleka kwefungal okungasakazeka egazini kuye kuwo wonke umzimba (fungemia).

Ukuqapha okukhethekile nezixwayiso:

Ukukhulelwa nokuncelisa ibele: Alukho ulwazi olwanele olwanele lokwazi ukuthi ngabe i-Saccharomyces boulardii iphephile ukusetshenziswa uma ukhulelwe noma uncelisa ibele. Hlala ohlangothini oluphephile futhi ugweme ukusetshenziswa.

Izingane: Saccharomyces boulardii kuyinto OKUNGENZEKA UKUPHEPHA ezinganeni lapho zithathwa ngomlomo ngokufanele. Kodwa-ke, isifo sohudo ezinganeni kufanele sihlolwe nguchwepheshe wezokunakekelwa kwempilo ngaphambi kokusebenzisa iSaccharomyces boulardii.

Asebekhulile: Asebekhulile bangaba nengozi eyengeziwe yokutheleleka kwefungal lapho bethatha iSaccharomyces boulardii. Hlala ohlangothini oluphephile futhi ugweme ukusetshenziswa.

Amasosha omzimba abuthakathaka: Kukhona okunye ukukhathazeka ngokuthi ukuthatha iSaccharomyces boulardii kungadala i-fungemia, okuwukuba khona kwemvubelo egazini. Inani langempela lamacala we-Saccharomyces boulardii-fungemia ahlobene kunzima ukuthola. Kodwa-ke, ingozi ibonakala inkulu kakhulu kubantu abagula kakhulu noma abenze buthaka amasosha omzimba. Ikakhulu, abantu abane-catheters, labo abathola i-tube feed, nalabo abaphathwa ngama-antibiotic amaningi noma ama-antibiotic asebenza ngezifo ezahlukahlukene babonakala besengozini enkulu. Ezimweni eziningi, i-fungemia ibangelwe ukungcoliswa nge-catheter yomoya, indawo ezungezile, noma izandla ezingcoliswe yi-Saccharomyces boulardii.

Ukungezwani komzimba nemvubelo: Abantu abanesifo semvubelo yokungezwani komzimba bangaba negciwane emikhiqizweni equkethe iSaccharomyces boulardii, futhi balulekwa kangcono ukuthi bagweme le mikhiqizo.

Okuncane
Qaphela ngale nhlanganisela.
Imithi yokwelashwa ngamafungal (Antifungals)
ISaccharomyces boulardii iyisikhunta. Imithi yokwelashwa ngamafungal isiza ekwehliseni ukhunta nasemzimbeni. Ukuthatha iSaccharomyces boulardii ngemithi yokutheleleka ngezifo kungakunciphisa ukusebenza kweSaccharomyces boulardii.
Eminye imishanguzo yokutheleleka ngefungal ifaka i-fluconazole (i-Diflucan), i-caspofungin (i-Cancidas), i-itraconazole (i-Sporanox) i-amphotericin (i-Ambisome), neminye.
Akukho ukuxhumana okwaziwayo ngamakhambi nezengezo.
Akukho ukuxhumana okwaziwayo nokudla.
Imithamo elandelayo ifundwe ocwaningweni lwesayensi:

ABADALA

NGOMLOMO:
  • Ukuze uhudo kubantu abathatha ama-antibiotics (isifo sohudo esihlobene ne-antibiotic): I-250-500 mg ye-Saccharomyces boulardii ethathwa izikhathi ezingama-2-4 nsuku zonke kuze kube amasonto ama-2 isetshenziswa kakhulu. Ezimweni eziningi, imithamo yansuku zonke ingeqi ku-1000 mg nsuku zonke.
  • Ngokutheleleka komgudu wamathumbu ngamagciwane abizwa ngeClostridium difficile: Ukuvimbela ukuphindeka, i-500 mg ye-Saccharomyces boulardii kabili ngosuku amasonto ama-4 kanye nokwelashwa kwama-antibiotic kusetshenzisiwe.
  • Ngokutheleleka kokugaya ukudla okungaholela ezilondeni (Helicobacter pylori noma H. ​​pylori)Kusetshenziswa kakhulu ama-500-1000 mg we-Saccharomyces boulardii nsuku zonke amasonto e-1-4.
  • Okokuhuda kubantu abane-HIV / AIDS: 3 amagremu weSaccharomyces boulardii nsuku zonke.
  • Okokuhuda kwabahambi: 250-1000 mg we-Saccharomyces boulardii nsuku zonke inyanga e-1.
IZINGANE

NGOMLOMO:
  • Ukuze uhudo kubantu abathatha ama-antibiotics (isifo sohudo esihlobene ne-antibiotic)Kusetshenziswe ama-250 mg we-Saccharomyces boulardii kanye noma kabili nsuku zonke isikhathi semithi elwa namagciwane.
  • Okwehudo: Ekwelapheni isifo sohudo esibuhlungu, kusetshenziswe ama-250 mg we-Saccharomyces boulardii kanye noma kabili nsuku zonke noma amayunithi okwakha amakoloni ayizigidi eziyizinkulungwane eziyishumi kanye ngosuku izinsuku ezinhlanu. Ekwelapheni isifo sohudo esiqhubekayo, kusetshenziswe amayunithi ayizigidi eziyizinkulungwane eziyi-1750 kuya kweziyi-175 trillion akha amakoloni eSaccharomyces boulardii kabili ngosuku izinsuku ezinhlanu. Ngokuvikela isifo sohudo kubantu abathola ama-feed feeding, kusetshenziswe ama-500 mg we-Saccharomyces boulardii amahlandla amane ngosuku.
  • Ngesifo sohudo esibangelwa i-rotavirusKusetshenziswe u-200-250 mg we-Saccharomyces boulardii kabili ngosuku izinsuku ezi-5.
  • Ngesifo samathumbu esibi ezinganeni ezingaphambi kwesikhathi (necrotizing enterocolitis noma i-NEC): 100-200 mg / kg Saccharomyces boulardii nsuku zonke, ukuqala ngesonto lokuqala ngemuva kokuzalwa.
I-Probiotic, Probiotique, Saccharomyces, Saccharomyces Boulardii CNCM I-745, Saccharomyces Boulardii HANSEN CBS 5926, Saccharomyces Boulardii Lyo CNCM I-745, Saccharomyces Boulardius, Saccharomyces Cerevisiae Boulardii, Saccharomyces Cerevisia Cassvisia ICerevisiae HANSEN CBS 5926, Saccharomyces cerevisiae var boulardii, S. Boulardii, SCB.

Ukuze ufunde kabanzi ngokuthi le ndatshana ibhalwe kanjani, sicela ubheke ifayela le- Imibhalo Yemvelo Yemininingwane Ephelele indlela.


  1. I-ID ye-Florez, i-Veroniki AA, i-Al Khalifah R, et al. Ukusebenza ngokuqhathanisa nokuphepha kokungenelela kohudo olubi kanye ne-gastroenteritis ezinganeni: Ukubuyekezwa okuhlelekile nokuhlaziywa kwe-meta-analysis. Ama-PLoS One. 2018; 13: e0207701. Buka okungaqondakali.
  2. UHarnett JE, uPyne DB, uMcKune AJ, uPenm J, uPumpa KL. Ukuxhaswa kwe-Probiotic kuvusa ushintsho oluhle ekukhathazekeni kwemisipha nekhwalithi yokulala kubadlali bombhoxo. J Sci Med Ezemidlalo. 2020: S1440-244030737-4. Buka okungaqondakali.
  3. UGao X, Wang Y, Shi L, Feng W, Yi K. Umphumela nokuphepha kwe-Saccharomyces boulardii ye-neonatal necrotizing enterocolitis ezinganeni zangaphambi kwesikhathi: Ukubuyekezwa okuhlelekile nokuhlaziywa kwemeta. UJ Trop Ingane yezingane. 2020: fmaa022. Buka okungaqondakali.
  4. UMourey F, Sureja V, Kheni D, et al. Isivivinyo esilawulwa yi-multicenter, randomized, blind-blind, se-placebo seSaccharomyces boulardii ezinganeni nasezinganeni ezinesifo sohudo esibi. I-Pediatr Infect Dis J. 2020; 39: e347-e351. Buka okungaqondakali.
  5. IKarbownik MS, Kr & eogon; czy & nacute; ska J, Kwarta P, et al. Umphumela wokwengeza nge-Saccharomyces boulardii ekusebenzeni kokuhlolwa kwezifundo kanye nengcindezi ehlobene nabafundi bezempilo abaphilile: Isivivinyo esilawulwa ngokungahleliwe, esingaboni kabili, esilawulwa yi-placebo. Izakhamzimba. 2020; 12: 1469. Buka okungaqondakali.
  6. UZhou BG, Chen LX, Li B, Wan LY, Ai YW. ISaccharomyces boulardii njengokwelashwa okunciphisayo kwe-Helicobacter pylori ukuqeda: Ukubuyekezwa okuhlelekile nokuhlaziywa kwe-meta nokuhlaziywa ngokulandelana kwesivivinyo. I-Helicobacter. 2019; 24: e12651. Buka okungaqondakali.
  7. USzajewska H, ​​uKolodziej M, uZalewski BM. Ukubuyekezwa okuhlelekile ngokuhlaziywa kwe-meta: ISaccharomyces boulardii yokwelapha i-gastroenteritis ebukhali ezinganeni-isibuyekezo se-2020. I-Aliment Pharmacol Ther. 2020. Buka okungaqondakali.
  8. USeddik H, uBoutallaka H, ​​u-Elkoti I, et al. ISaccharomyces boulardii CNCM I-745 kanye nokwelashwa okulandelanayo kwezifo zeHelicobacter pylori: isilingo esingahleliwe, esinelebuli evulekile. I-Eur J Clin Pharmacol. 2019; 75: 639-645. Buka okungaqondakali.
  9. UGarcía-Collinot G, uMadrigal-Santillán EO, uMartínez-Bencomo MA, et al. Ukusebenza kweSaccharomyces boulardii neMetronidazole ye-Small Intestinal Bacterial Overgrowth in Systemic Sclerosis. IDig Dis Sci. 2019. Buka okungaqondakali.
  10. UMcDonald LC, uGerding DN, uJohnson S, et al .; I-Infectious Diseases Society of America. Imihlahlandlela yokusebenza kwemitholampilo yokutheleleka ngeClostridium difficile kubantu abadala nasezinganeni: Ukubuyekezwa kwe-2017 yi-Infectious Diseases Society of America (IDSA) kanye neSoccer of Healthcare Epidemiology of America (SHEA). Izifo Ezithathelwanayo Zemitholampilo 2018; 66: e1-e48.
  11. UXu L, uWang Y, uWang Y, et al. Isivivinyo esenziwe izimpumputhe esikabili ekukhuleni nasekubekezeleleni ukondla ngeSaccharomyces boulardii CNCM I-745 ezinganeni ezisencane ezifundiswe ifomula. UJ Pediatr (Rio J). 2016; 92: 296-301. Buka okungaqondakali.
  12. USheele J, uCartowski J, uDart A, et al. I-Saccharomyces boulardii ne-bismuth subsalicylate njengezindlela zokungenelela eziphansi ukwehlisa ubude nobukhulu bekholera. I-Pathog Glob Health. 2015; 109: 275-82. Buka okungaqondakali.
  13. URyan JJ, uHanes DA, uSchafer MB, uMikolai J, uZwickey H. Umphumela weProbiotic Saccharomyces boulardii kuCholesterol naseLipoprotein Particles ku-Hypercholesterolemic Adult: A Single-Arm, Open-Label Pilot Study. UJ Altern Complement Med. 2015; 21: 288-93. Buka okungaqondakali.
  14. I-Flatley EA, i-Wilde AM, i-Nailor MD. ISaccharomyces boulardii yokuvimbela ukuqala kwesibhedlela ukutheleleka ngeClostridium difficile. J Gastrointestin Isibindi Dis. 2015; 24: 21-4. Buka okungaqondakali.
  15. U-Ehrhardt S, uGuo N, uHinz R, et al. ISaccharomyces boulardii Ukuvimbela Isifo sohudo Esihlobene Nemithi Elwa Namagciwane: Isivivinyo Esilawulwa Ngokungahleliwe, Esifihliwe Kababili, Esilawulwa Ngeplacebo. Vula i-Forum Infect Dis. 2016; 3: ye-w011. Buka okungaqondakali.
  16. UDinleyici EC, uKara A, uDalgic N, et al. ISaccharomyces boulardii CNCM I-745 inciphisa isikhathi sohudo, ubude bokunakekelwa okuphuthumayo nokuhlala esibhedlela ezinganeni ezinesifo sohudo esibi. Zuza Amagciwane. 2015; 6: 415-21. Buka okungaqondakali.
  17. UDauby N. Izingozi zeSaccharomyces boulardii-Equkethe amaProbiotic Wokuvimbela Ukutheleleka KweClostridium difficile Kwasebekhulile. I-Gastroenterology. 2017; 153: 1450-1451. Buka okungaqondakali.
  18. UCottrell J, Koenig K, Perfekt R, Hofmann R; ILoperamide-Simethicone Acute Diarrhea Team Ithimba. Ukuqhathaniswa Kwezinhlobo Ezimbili zeLoperamide-Simethicone kanye neProbiotic Yeast (Saccharomyces boulardii) ekwelashweni kwesifo sohudo esibukhali kubantu abadala: Isivivinyo Somtholampilo Esingahleliwe Esingahleliwe. Izidakamizwa R D. 2015; 15: 363-73. Buka okungaqondakali.
  19. ICostanza AC, Moscavitch SD, Faria Neto HC, Mesquita ET. Ukwelashwa kwe-Probiotic nge-Saccharomyces boulardii yeziguli ezihluleka yinhliziyo: isilingo esilawulwa ngokungahleliwe, esingaboni kahle, esilawulwa yi-placebo. I-Int J Cardiol. 2015; 179: 348-50. Buka okungaqondakali.
  20. UCarstensen JW, uChehri M, uSchningnning K, et al. Ukusetshenziswa kwe-prophylactic Saccharomyces boulardii ukuvimbela ukutheleleka kweClostridium difficile ezigulini ezibhedlela: isifundo esilawulwayo sokungenelela okulawulwayo. I-Eur J Clin Microbiol Infect Dis. 2018; 37: 1431-1439. Buka okungaqondakali.
  21. Asmat S, Shaukat F, Asmat R, Bakhat HFSG, Asmat TM. Ukuqhathaniswa Kokusebenza Kwezemitholampilo kweSaccharomyces Boulardii neLactic Acid njengamaProbiotic ku-Acute Pediatric Diarrhea. J Coll Odokotela Abahlinzayo Pak. I-2018; 28: 214-217. Buka okungaqondakali.
  22. URemenova T, uMorand O, u-Amato D, uChadha-Boreham H, uTurutani S, uMarquardt T. Isivivinyo esilawulwa kabili, esingahleliwe, esilawulwa nge-placebo esifundisisa ngemiphumela yeSaccharomyces boulardii ekubekezeleleni kwamathumbu, ukuphepha, kanye ne-pharmacokinetics yemiglustat. I-Orphanet J Rare Dis 2015; 10: 81. Buka okungaqondakali.
  23. USuganthi V, uDas AG. Indima yeSaccharomyces boulardii ekwehliseni i-neonatal hyperbilirubinemia. I-J Clin Diagn Res 2016; 10: SC12-SC15. Buka okungaqondakali.
  24. URiaz M, Alam S, Malik A, Ali SM. Ukusebenza nokuphepha kwe-Saccharomyces boulardii kuhudo olunzima lwezingane: isilingo esilawulwa kabili esilawulwa ngokungahleliwe. I-Indian J Pediatr 2012; 79: 478-82. Buka okungaqondakali.
  25. - UCorrêa NB, uPenna FJ, uLima FM, uNicoli JR, uFoho LA. Ukwelashwa kohudo olubi nge-Saccharomyces boulardii ezinganeni. J Pediatr Gastroenterol Nutriti 2011; 53: 497-501. Buka okungaqondakali.
  26. UCohen SH, uGerding DN, uJohnson S, et al .; Inhlangano Yezempilo Epidemiology yaseMelika; I-Infectious Diseases Society of America. Imihlahlandlela yokwenziwa kwemitholampilo yokutheleleka ngeClostridium difficile kubantu abadala: Ukuvuselelwa kuka-2010 ngumphakathi we-healthcare epidemiology of America (SHEA) kanye nomphakathi wezifo ezithathelwanayo waseMelika (IDSA). I-Infect Control Hosp Epidemiol 2010; 31: 431-55. Buka okungaqondakali.
  27. UGoldenberg JZ, Ma SS, uSaxton JD, et al. Ama-Probiotic wokuvimbela isifo sohudo esihambisana neClostridium difficile kubantu abadala nasezinganeni. ICochrane Database Syst Rev. 2013;: CD006095. Buka okungaqondakali.
  28. ILau CS, uChamberlain RS. Ama-Probiotic ayasebenza ekuvimbeleni isifo sohudo esihambisana neClostridium difficile: ukubuyekeza okuhlelekile nokuhlaziywa kwemeta. Int J Gen Med. 2016; 9: 27-37. Buka okungaqondakali.
  29. URoy U, uJessani LG, uRudramurthy SM, et al. Amacala ayisikhombisa eSaccharomyces fungaemia ahlobene nokusetshenziswa kwamaphrobiotic. I-Mycoses 2017; 60: 375-380. Buka okungaqondakali.
  30. URomanio MR, uCoraine LA, uMaielo VP, u-Abramczyc ML, uSouza RL, u-Oliveira NF. I-Saccharomyces cerevisiae fungemia esigulini sezingane ngemuva kokwelashwa ngama-probiotic. UMfu Paul Pediatr 2017; 35: 361-4. Buka okungaqondakali.
  31. UPozzzoni P, uRiva A, uBellatorre AG, et al. ISaccharomyces boulardii yokuvimbela uhudo oluhambisana nemithi elwa namagciwane ezigulini zabantu abadala ezibhedlela: isikhungo esisodwa, esingahleliwe, esiyimpumputhe, isilingo esilawulwa yi-placebo. NginguJ J Gastroenterol 2012; 107: 922-31. Buka okungaqondakali.
  32. UMartin IW, uTonner R, uTrivedi J, et al. I-Saccharomyces boulardii i-probiotic ehlobene ne-fungemia: ukubuza ukuphepha kwalokhu kusetshenziswa kwama-probiotic wokuvikela. Thola i-Microbiol Infect Dis. 2017; 87: 286-8. Buka okungaqondakali.
  33. UChoi CH, uJo SY, iPark HJ, uChang SK, uByeon JS, uMyung SJ. Isivivinyo se-Saccharomyces boulardii esilawulwa ngokungahleliwe, esimpumputhe kabili, esilawulwa yi-placebo seSaccharomyces boulardii ku-irritable bowel syndrome: umphumela wempilo. UJ Clin Gastroenterol. 2011; 45: 679-83. Buka okungaqondakali.
  34. U-Atici S, uSoysal A, uKaradeniz Cerit K, et al. I-Saccharomyces cerevisiae Fungemia ehlobene ne-Catheter elandela i-Saccharomyces boulardii Ukwelashwa kwama-Probiotic: Enganeni esegunjini labagula kakhulu nokubuyekezwa kwezincwadi. I-Med Mycol Case Rep. 2017; 15: 33-35. Buka okungaqondakali.
  35. U-Appel-da-Silva MC, uNarvaez GA, uPerez LRR, uDrehmer L, uLewgoy J. Saccharomyces cerevisiae var. i-boulardii fungemia elandela ukwelashwa kwama-probiotic. I-Med Mycol Case Rep. 2017; 18: 15-7. Buka okungaqondakali.
  36. Chang HY, Chen JH, Chang JH, Lin HC, Lin CY, Peng CC. Ama-probiotic wamagciwane amaningi abonakala njengama-probiotic asebenza kakhulu ekuvikeleni i-necrotizing enterocolitis kanye nokufa: Ukuhlaziywa kwe-meta-ukuhlaziywa. Ama-PLoS One. 2017; 12: e0171579. Buka okungaqondakali.
  37. IBlaabjerg S, Artzi DM, Aabenhus R. Probiotic for the Prevention of Antibiotic-Associated Diarrhea in Outpatients-A Systematic Review and Meta-Analysis. Ama-Antibiotic (iBasel). 2017; 6. Buka okungaqondakali.
  38. I-Al Faleh K, i-Anabrees J. Probiotic yokuvimbela i-necrotizing enterocolitis ezinganeni ezizalwe ngaphambi kwesikhathi. ICochrane Database Syst Rev. 2014;: CD005496. Buka okungaqondakali.
  39. UDas S, uGupta PK, uDas RR. Ukusebenza Nokuphepha kwe-Saccharomyces boulardii ku-Acute Rotavirus Isifo sohudo: Isivivinyo Esilawulwa Ngokungahleliwe Esilawulwa Ngezwe Esivela Ezweni Elithuthukayo. UJ Trop Ingane yezingane. 2016; 62: 464-470. Buka okungaqondakali.
  40. IGoldenberg JZ, uLytvyn L, uSteurich J, uParkin P, uMahant S, uJohnston BC. Ama-Probiotic wokuvimbela isifo sohudo esihambisana nezingane. ICchrane Database Syst Rev. 2015;: CD004827. Buka okungaqondakali.
  41. I-Feizizadeh S, Salehi-Abargouei A, Akbari V. Ukusebenza nokuphepha kweSaccharomyces boulardii yohudo olubi. Izifo zezingane. 2014; 134: e176-191. Buka okungaqondakali.
  42. USzajewska H, ​​Horvath A, Kolodziej M. Ukubuyekezwa okuhlelekile nge-meta-analysis: Saccharomyces boulardii ukwengeza nokuqeda ukutheleleka kweHelicobacter pylori. I-Aliment Pharmacol Ther. 2015; 41: 1237-1245. Buka okungaqondakali.
  43. I-Szajewska H, ​​i-Kolodziej M. Ukubuyekezwa okuhlelekile nge-meta-analysis: Saccharomyces boulardii ekuvikeleni isifo sohudo esihlobene namagciwane. I-Aliment Pharmacol Ther. 2015; 42: 793-801. Buka okungaqondakali.
  44. U-Ellouze O, uBerthoud V, uMervant M, uParthiot JP, uGirard C. Ukushaqeka kwe-Septic ngenxa yeSacccaromyces boulardii. Igciwane le-Med Mal. 2016; 46: 104-105. Buka okungaqondakali.
  45. IBafutto M, et al. Ukwelashwa kwesifo sohudo-okubaluleke kakhulu okucasula isisu nge-mesalamine kanye / noma iSaccharomyces boulardii. I-Arq Gastroenterol. 2013; 50: 304-309. Buka okungaqondakali.
  46. UBourreille A, et al. ISaccharomyces boulardii ayikuvimbeli ukubuyela emuva kwesifo sikaCrohn. Umtholampilo Gastroenterol Hepatol. 2013; 11: 982-987.
  47. USerce O, Gursoy T, Ovali F, Karatekin G. Imiphumela yeSaccaromyces boulardii kwi-neonatal hyperbilirubinemia: isilingo esilawulwa ngokungahleliwe. NginguJ Perinatol. 2015; 30: 137-142. Buka okungaqondakali.
  48. IVidelock EJ, iCremonini F. Meta-analysis: ama-probiotic kuhudo oluhambisana nemithi elwa namagciwane. I-Aliment Pharmacol Ther. 2012; 35: 1355-69. Buka okungaqondakali.
  49. UHempel S, Newberry SJ, Maher AR, Wang Z, Miles JN, Shanman R, Johnsen B, Shekelle PG. Ama-Probiotic wokuvimbela nokwelashwa kwesifo sohudo esihambisana namagciwane: ukubuyekeza okuhlelekile nokuhlaziywa kwemeta. JAMA. 2012 9; 307: 1959-69. Buka okungaqondakali.
  50. U-Elmer GW, uMoyer KA, Vega R, no-al. Ukuhlolwa kweSaccharomyces boulardii yeziguli ezinesifo sohudo esingapheli esihlobene ne-HIV kanye namavolontiya anempilo athola ama-antifungal. IMicroecology Ther 1995; 25: 23-31.
  51. UPotts L, uLewis SJ, kanye noBarry R. Ukuhlola okulawulwa okungahleliwe okuphindwe kabili kwe-placebo okulawulwa kwekhono le-Saccharomyces boulardii ukuvimbela uhudo oluhlobene nama-antibiotic [abstract]. IGut 1996; 38 (suppl 1): A61.
  52. I-Bleichner G ne-Blehaut H. Saccharomyces boulardii ivimbela isifo sohudo ezigulini eziguliswa kabi ngamathambo. Isivivinyo esilawulwa yi-multicenter, randomized, blind-blind placebo [abstract]. I-Clin Nutr 1994; 13 Suppl 1:10.
  53. UMaupas JL, uChampemont P, noDelforge M. [Ukwelashwa kwesifo samathumbu esingacasuki nge-Saccharomyces boulardii - isifundo esilawulwa izimpumputhe ezimbili, esilawulwa yi-placebo]. UMédicine et Chirurgie Digestives 1983; 12: 77-79.
  54. USaint-Marc T, uBlehaut H, uMusial C, no-al. [Uhudo oluhlobene nengculazi: ukuhlolwa kwempumputhe kabili kwe-Saccharomyces boulardii]. USemaine Des Hopitaux 1995; 71 (23-24): 735-741.
  55. UMcFarland LV, uSurawicz C, uGreenberg R, no-al. ISaccharomyces boulardii kanye nomthamo ophakeme we-vancomycin uphatha isifo esiphindaphindayo seClostridium difficile [abstract]. NginguJ J Gastroenterol 1998; 93: 1694.
  56. UChouraqui JP, uDietsch J, uMusial C, no-al. I-Saccharomyces boulardii (SB) ekuphathweni kwesifo sohudo esisacathula: isifundo esilawulwa i-placebo esiyimpumputhe [abstract]. UJ Pediatr Gastroenterol Nutriti 1995; 20: 463.
  57. ICetina-Sauri G neBasto GS. I-Evaluacion terapeutica de Saccharomyces boulardii en ninos con diarrea aguda. I-Tribuna Med 1989; 56: 111-115.
  58. U-Adam J, uBarret C, uBarret-Bellet A, no-al. Ama-Essais cliniques controles en double insu de l'Ultra-Levure Lyophilisee. Etude multicentrique par 25 medecins de 388 cas. IGaz Med Fr 1977; 84: 2072-2078.
  59. UMcFarland LV, uSurawiczCM, u-Elmer GW, no-et al. Ukuhlaziywa kwe-multivariate kokusebenza komtholampilo kwe-ejenti ye-biotherapeutic, iSaccharomyces boulardii yokuvimbela isifo sohudo esihambisana nemithi elwa namagciwane [abstract]. Ngingu-J Epidemiol 1993; 138: 649.
  60. USaint-Marc T, uRossello-Prats L, noTouraine JL. [Ukusebenza kweSaccharomyces boulardii ekuphathweni kwesifo sohudo se-AIDS]. U-Ann Med Interne (eParis) ngo-1991; 142: 64-65.
  61. UKirchhelle, A., Fruhwein, N., noToburen, D. [Ukwelashwa kohudo oluqhubekayo no-S. boulardii kubahambi ababuyayo. Imiphumela yocwaningo olulindelekile]. I-Fortschr Med 4-20-1996; 114: 136-140. Buka okungaqondakali.
  62. U-Born, P., Lersch, C., Zimmerhackl, B., noClassen, M. [Ukwelashwa kwe-Saccharomyces boulardii yokwelashwa okuhambisana ne-HIV]. UDtsch Med Wochenschr 5-21-1993; 118: 765. Buka okungaqondakali.
  63. UKollaritsch, H., Holst, H., Grobara, P., noWiedermann, G. [Ukuvimbela isifo sohudo ngeSaccharomyces boulardii. Imiphumela ye-placebo elawulwa kabili eyimpumputhe yokufunda]. I-Fortschr. Meded 3-30-1993; 111: 152-156. Buka okungaqondakali.
  64. Tempe, J. D., Steidel, A. L., Blehaut, H., Hasselmann, M., Lutun, P., noMaurier, F. [Ukuvimbela isifo sohudo okuhlinzeka iSaccharomyces boulardii ngesikhathi sokudla okuqhubekayo]. Sem.Hop. 5-5-1983; 59: 1409-1412. Buka okungaqondakali.
  65. I-Chapoy, P. [Ukwelashwa kwesifo sohudo esibuhlungu kakhulu: isilingo esilawulwayo se-Saccharomyces boulardii]. U-Ann Pediatr. (EParis) 1985; 32: 561-563. Buka okungaqondakali.
  66. UKimmey, M. B., Elmer, G. W., Surawicz, C. M., noMcFarland, L. V. Ukuvimbela ukuphinda kuqhubeke kweClostridium difficile colitis ne-Saccharomyces boulardii. I-Dig. Dis Sci 1990; 35: 897-901. Buka okungaqondakali.
  67. USaint-Marc, T., Rossello-Prats, L., noTouraine, J. L. [Ukusebenza kweSaccharomyces boulardii ekwelapheni isifo sohudo ku-AIDS]. U-Ann Med Interne (eParis) ngo-1991; 142: 64-65. Buka okungaqondakali.
  68. UDuman, DG, Bor, S., Ozutemiz, O., Sahin, T., Oguz, D., Istan, F., Vural, T., Sandkci, M., Isksal, F., Simsek, I., Soyturk. , M., Arslan, S., Sivri, B., Soykan, I., Temizkan, A., Bessk, F., Kaymakoglu, S., noKalayc, C. Ukusebenza nokuphepha kwe-Saccharomyces boulardii ekuvimbeleni i-antibiotic- uhudo oluhambisana nalo ngenxa yokuqedwa kweHelicobacterpylori I-Eur J Gastroenterol. I-hepatol. 2005; 17: 1357-1361. Buka okungaqondakali.
  69. Surawicz, C. M. Ukwelashwa kwesifo esihlobene ne-Clostridium difficile. I-Nat Clin Pract. I-Gastroenterol, i-hepatol. 2004; 1: 32-38. Buka okungaqondakali.
  70. UKurugol, Z. noKoturoglu, G. Imiphumela yeSaccharomyces boulardii ezinganeni ezinesifo sohudo esibi. I-Acta Paediatr. 2005; 94: 44-47. Buka okungaqondakali.
  71. UKotowska, M., Albrecht, P., noSzajewska, H. Saccharomyces boulardii ekuvikeleni uhudo oluhambisana namagciwane ezinganeni: isilingo esilawulwa ngokungahleliwe esilawulwa yi-placebo. I-Aliment.I-Pharmacol.Ther. 3-1-2005; 21: 583-590. Buka okungaqondakali.
  72. UCherifi, S., Robberecht, J., noMiendje, Y. Saccharomyces cerevisiae fungemia esigulini esikhulile esineClostridium difficile colitis. I-Acta Clin Belg. 2004; 59: 223-224. Buka okungaqondakali.
  73. U-Erdeve, O., Tiras, U., noDallar, Y. Umphumela we-probiotic weSaccharomyces boulardii eqenjini lobudala bezingane. J Trop. Udokotela wezingane. 2004; 50: 234-236. Buka okungaqondakali.
  74. I-Costalos, C., Skouteri, V., Gounaris, A., Sevastiadou, S., Triandafilidou, A., Ekonomidou, C., Kontaxaki, F., no-Petrochilou, V. Ukudla okungapheli kwezinsana ezingakazalwa nge-Saccharomyces boulardii. Umuntu Wasekuqaleni. 2003; 74: 89-96. Buka okungaqondakali.
  75. UGaon, D., Garcia, H., Winter, L., Rodriguez, N., Quintas, R., Gonzalez, S. N., no-Oliver, G. Umphumela wezinhlobo zeLactobacillus kanye neSaccharomyces boulardii kuhudo oluqhubekayo ezinganeni. IMedicina (B Aires) 2003; 63: 293-298. Buka okungaqondakali.
  76. UMansour-Ghanaei, F., Dehbashi, N., Yazdanparast, K., noShafaghi, A. Ukusebenza kwe-saccharomyces boulardii ngama-antibiotics kuma-amoebiasis abukhali. Umhlaba J Gastroenterol. 2003; 9: 1832-1833. Buka okungaqondakali.
  77. URiquelme, A. J., Calvo, M. A., uGuzman, A.M., Depix, M. S., Garcia, P., Perez, C., Arrese, M., noLabarca, J. A. Saccharomyces cerevisiae fungemia ngemuva kokwelashwa kwe-Saccharomyces boulardii ezigulini ezingenakunyakaziswa. J Umtholampilo. Gastroenterol. 2003; 36: 41-43. Buka okungaqondakali.
  78. I-Cremonini, F., Di Caro, S., Santarelli, L., Gabrielli, M., Candelli, M., Nista, EC, Lupascu, A., Gasbarrini, G., noGarbarrini, A. Ama-Probiotic kuma-antibiotic ahlobene isifo sohudo. I-Dig Dig 2002; 34 Isilinganiso 2: S78-S80. Buka okungaqondakali.
  79. Lherm, T., Monet, C., Nougiere, B., Soulier, M., Larbi, D., Le Gall, C., Caen, D., noMalbrunot, C. Amacala ayisikhombisa e-fungemia ane-Saccharomyces boulardii ngokugxeka iziguli ezigulayo. Ukunakekelwa Okukhulu Med 2002; 28: 797-801. Buka okungaqondakali.
  80. UTasteyre, A., Barc, M. C., Karjalainen, T., Bourlioux, P., noCollignon, A. Ukuvinjelwa kokunamathela kwe-in vitro cell kweClostridium difficile yiSaccharomyces boulardii. I-Microb.Pathog. 2002; 32: 219-225. Buka okungaqondakali.
  81. UShanahan, F. Ama-Probiotic ezifweni ezivuthayo zamathumbu. Isisu 2001; 48: 609. Buka okungaqondakali.
  82. Surawicz, CM, McFarland, LV, Greenberg, RN, Rubin, M., Fekety, R., Mulligan, ME, Garcia, RJ, Brandmarker, S., Bowen, K., Borjal, D., no-Elmer, GW The funa ukwelashwa okungcono kwesifo esivela njalo seClostridium difficile: ukusetshenziswa kwe-high-dose vancomycin kuhlanganiswe ne-Saccharomyces boulardii. Umtholampilo. Ukutheleleka. 2000; 31: 1012-1017. Buka okungaqondakali.
  83. UJohnston BC, Ma SSY, uGoldenberg JZ, et al. Ama-Probiotic wokuvimbela isifo sohudo esihambisana neClostridium difficile. U-Ann Intern Med 2012; 157: 878-8. Buka okungaqondakali.
  84. UMunoz P, uBouza E, uCuenca-Estrella M, et al. I-Saccharomyces cerevisiae fungemia: isifo esithathelwanayo esiqhamukayo. I-Clin Infect Dis 2005; 40: 1625-34. Buka okungaqondakali.
  85. Szajewska H, ​​Mrukowicz J. Meta-analysis: non-pathogenic yeast Saccharomyces boulardii ekuvikeleni isifo sohudo esihambisana namagciwane. I-Aliment Pharmacol Ther 2005; 22: 365-72. Buka okungaqondakali.
  86. Ngabe uM, uBesirbellioglu BA, u-Avci IY, et al. I-Prophylactic Saccharomyces boulardii ekuvikeleni isifo sohudo esihambisana nemithi elwa namagciwane: Umuntu ongafunda ngaye. IMed Sci Monit 2006; 12: PI19-22. Buka okungaqondakali.
  87. UGuslandi M, uGiollo P, iTestoni PA. Isivivinyo somshayeli weSaccharomyces boulardii ku-ulcerative colitis. I-Eur J Gastroenterol Hepatol 2003; 15: 697-8. Buka okungaqondakali.
  88. UGuslandi M, Mezzi G, Sorghi M, Testoni PA. ISaccharomyces boulardii ekwelapheni ukwelashwa kwesifo sikaCrohn. I-Dig Dis Sci 2000; 45: 1462-4. Buka okungaqondakali.
  89. IMcFarland LV. Ukuhlaziywa kwe-meta kwama-probiotic wokuvimbela isifo sohudo esihambisana namagciwane kanye nokwelashwa kwesifo seClostridium difficile. NginguJ J Gastroenterol 2006; 101: 812-22. Buka okungaqondakali.
  90. UMarteau P, uSeksik P. Ukubekezelela ama-probiotic kanye nama-prebiotic. UJ Clin Gastroenterol 2004; 38: S67-9. Buka okungaqondakali.
  91. UBorriello SP, uHammes WP, uHolzapfel W, et al. Ukuphepha kwama-probiotic aqukethe i-lactobacilli noma i-bifidobacteria. I-Clin Infect Dis 2003; 36: 775-80. Buka okungaqondakali.
  92. ICremonini F, uDi Caro S, uCovino M, et al. Umphumela wamalungiselelo ahlukile wama-probiotic emiphumeleni emibi ehlobene nokwelashwa kwe-anti-helicobacter pylori: iqembu elifanayo, izimpumputhe eziphindwe kathathu, isifundo esilawulwa nge-placebo. NginguJ J Gastroenterol 2002; 97: 2744-9. Buka okungaqondakali.
  93. UD'Souza AL, Rajkumar C, Cooke J, Bulpitt CJ. Ama-Probiotic ekuvimbeleni isifo sohudo esihambisana namagciwane: ukuhlaziywa kwe-meta. BMJ 2002; 324: 1361. Buka okungaqondakali.
  94. UMuller J, Remus N, uHarms KH. Ucwaningo lwe-Mycoserological lokwelashwa kweziguli ze-cystic fibrosis ezingane ezine-Saccharomyces boulardii (Saccharomyces cerevisiae Hansen CBS 5926). I-Mycoses 1995; 38: 119-23. Buka okungaqondakali.
  95. I-Plein K, i-Hotz J. Imiphumela yokwelashwa kwe-Saccharomyces boulardii ngezimpawu ezisele eziyinsalela esigabeni esizinzile sesifo sikaCrohn ngokuhlonipha okukhethekile kuhudo olungapheli - isifundo somshayeli. UZ Gastroenterol 1993; 31: 129-34. Buka okungaqondakali.
  96. UHennequin C, uThierry A, uRichard GF, et al. Ukuthayipha kweMicrosatellite njengethuluzi elisha lokuhlonza izinhlobo zeSaccharomyces cerevisiae. UJ Clin Microbiol 2001; 39: 551-9. Buka okungaqondakali.
  97. UCesaro S, Chinello P, Rossi L, Zanesco L. Saccharomyces cerevisiae fungemia esigulini se-neutropenic esiphathwe nge-Saccharomyces boulardii. Ukusekela Umdlavuza Wokunakekela 2000; 8: 504-5. Buka okungaqondakali.
  98. U-Weber G, Adamczyk A, Freytag S. [Ukwelashwa kwezinduna ngokulungiswa kwemvubelo]. I-Fortschr Med 1989; 107: 563-6. Buka okungaqondakali.
  99. U-Lewis SJ, Freedman AR. Buyekeza i-athikili: ukusetshenziswa kwama-biotherapeutic agents ekuvimbeleni nasekwelapheni izifo zamathumbu. I-Aliment Pharmacol Ther 1998; 12: 807-22. Buka okungaqondakali.
  100. I-Krammer M, Karbach U. Isenzo se-Antidiarrheal sokwenza imvubelo i-Saccharomyces boulardii egundeni amathumbu amancane namakhulu ngokuvuselela ukumunca i-chloride. UZ Gastroenterol 1993; 31: 73-7.
  101. UCzerucka D, uRoux I, uRampal P. Saccharomyces boulardii uvimbela i-adenosine 3 ', 5'-cyclic monophosphate induction kumaseli emathumbu. IGastroenterol 1994; 106: 65-72. Buka okungaqondakali.
  102. U-Elmer GW, uMcFarland LV, uSurawicz CM, et al. Ukuziphatha kweSaccharomyces boulardii ezigulini eziphindaphindayo zezifo zeClostridium difficile. I-Aliment Pharmacol Ther 1999; 13: 1663-8. Buka okungaqondakali.
  103. UFredenucci I, uChomarat M, uBoucaud C, et al. I-Saccharomyces boulardii fungemia esigulini esithola ukwelashwa kwe-ultra-levure. I-Clin Infect Dis 1998; 27: 222-3. Buka okungaqondakali.
  104. UPletinex M, Legein J, Vandenplas Y. Fungemia oneSaccharomyces boulardii entombazaneni eneminyaka engu-1 enesifo sohudo esinesikhathi eside. UJ Pediatr Gastroenterol Nutriti 1995; 21: 113-5. Buka okungaqondakali.
  105. I-Buts JP, Corthier G, Delmee M. Saccharomyces boulardii yama-enteropathies ahlobene neClostridium difficile ezinganeni. UJ Pediatr Gastroenterol Nutrit 1993; 16: 419-25. Buka okungaqondakali.
  106. ISurawicz CM, u-Elmer GW, uSpeelman P, et al. Ukuvimbela isifo sohudo esihambisana nemithi elwa namagciwane yiSaccharomyces boulardii: isifundo esizoba khona. I-Gastroenterology 1989; 96: 981-8. Buka okungaqondakali.
  107. ISurawicz CM, McFarland LV, Elmer G, et al. Ukwelashwa kwe-recostrent clostridium difficile colitis nge-vancomycin ne-Saccharomyces boulardii. NginguJ J Gastroenterol 1989; 84: 1285-7. Buka okungaqondakali.
  108. UMcFarland LV, uSurawicz CM, uGreenberg RN, et al. Ukuvimbela isifo sohudo esihambisana ne-beta-lactam yi-Saccharomyces boulardii kuqhathaniswa ne-placebo. NginguJ J Gastroenterol 1995; 90: 439-48. Buka okungaqondakali.
  109. UMcFarland LV, uSurawicz CM, uGreenberg RN, et al. Isivivinyo esilawulwa ngokungahleliwe se-placebo seSaccharomyces boulardii ngokuhlanganiswa nama-antibiotic ajwayelekile wesifo seClostridium difficile. I-JAMA 1994; 271: 1913-8. Buka okungaqondakali.
  110. I-Elmer GW, iMcFarland LV. Phawula ngokungabikho komphumela wokwelapha weSaccharomyces boulardii ekuvikeleni isifo sohudo esihlobene namagciwane ezigulini esezikhulile. J Ukuthelela 1998; 37: 307-8. Buka okungaqondakali.
  111. U-Lewis SJ, Potts LF, uBarry RE. Ukuntuleka komphumela wokwelapha weSaccharomyces boulardii ekuvikeleni isifo sohudo esihlobene namagciwane ezigulini esezikhulile. J Ukutheleleka 1998; 36: 171-4. Buka okungaqondakali.
  112. UBleichner G, uBlehaut H, uMentec H, et al. ISaccharomyces boulardii ivimbela isifo sohudo ezigulini eziguleliswe kabi ngamashubhu. Ukunakekelwa Okukhulu Med 1997; 23: 517-23. Buka okungaqondakali.
  113. UCastagliuolo I, uRiegler MF, uValenick L, et al. I-Saccharomyces boulardii protease ivimbela imiphumela yobuthi be-clostridium difficile A no-B ku-mucosa womuntu we-colonic. Ukutheleleka kanye ne-Immun 1999; 67: 302-7. Buka okungaqondakali.
  114. I-Saavedra J. Ama-Probiotic nohudo oluthathelwanayo. NginguJ J Gastroenterol 2000; 95: S16-8. Buka okungaqondakali.
  115. IMcFarland LV. ISaccharomyces boulardii akuyona iSaccharomyces cerevisiae. I-Clin Infect Dis 1996; 22: 200-1. Buka okungaqondakali.
  116. UMcCullough MJ, uClemons KV, uMcCusker JH, uStevens DA. Ukuhlonza izinhlobo nezinhlobo ezinobungozi be-Saccharomyces boulardii (nom. Inval.). UJ Clin Microbiol 1998; 36: 2613-7. Buka okungaqondakali.
  117. UNiault M, uThomas F, uProst J, et al. I-Fungemia ngenxa yezinhlobo ze-Saccharomyces esigulini esiphathwe nge-enteral Saccharomyces boulardii. I-Clin Infect Dis 1999; 28: 930. Buka okungaqondakali.
  118. UBassetti S, Frei R, Zimmerli W. Fungemia oneSaccharomyces cerevisiae ngemuva kokwelashwa ngeSaccharomyces boulardii. NginguJ Med 1998; 105: 71-2. Buka okungaqondakali.
  119. I-Scarpignato C, i-Rampal P. Ukuvimbela nokwelashwa kwesifo sohudo somhambi: Indlela yokwelashwa kwemithi. I-Chemotherapy 1995; 41: 48-81. Buka okungaqondakali.
Kugcine ukubuyekezwa - 11/10/2020

Izincwadi Ezintsha

Ingabe i-Emojis Limit Girls to Stereotypes?
Ukudlala

Ingabe i-Emojis Limit Girls to Stereotypes?

Uyathanda noma ungathandi, ama-emoji a ephenduke indlela ebalulekile yokuxhumana-hhayi nje eyent ha. (Igama elaziwa kakhulu ngo-2014 kwakuyi-emoji yenhliziyo. Lokho akulona ngi ho negama!) Uku hint ha...
Ungahlala Kanjani Ugxilile Lapho Ucindezelekile Futhi Ukhungathekile
Ukudlala

Ungahlala Kanjani Ugxilile Lapho Ucindezelekile Futhi Ukhungathekile

Uma unenkinga yokugxili a ingqondo, wamukelekile kokujwayelekile oku ha. Ci he unyaka owodwa ngemuva kokuqala ukungena kukhiye, iningi lethu li alwa kanzima u uku lonke nokuphazami eka. Ngokunaka ukuk...